Sanofi India Limited has published its audited financial results for the quarter and year ended December 31, 2025, in leading newspapers including Business Standard and Sakal. The pharmaceutical company's results reveal mixed performance with declining overall revenue but strong growth in its core diabetes franchise.

Financial Performance Overview

The company's financial results show a challenging year with total income from operations declining 9% year-over-year to ₹18,571 million in FY25 from ₹20,297 million in FY24. This decline was primarily attributed to reduced export sales, which dropped significantly by 40% to ₹2,244 million from ₹3,725 million in the previous year.

Quarterly Performance Analysis

The Q4 FY25 quarterly results showed total income from operations at ₹4,226 million compared to ₹5,208 million in Q4 FY24, representing a decline from the previous year. Net profit before tax and exceptional items for the quarter stood at ₹830 million, while net profit after tax was ₹617 million.

Earnings Per Share and Dividend Distribution

The company's earnings per share for FY25 improved to ₹141.85 from ₹136.21 in the previous year, reflecting better profitability despite revenue challenges. The board has proposed a 5% increase in total dividend for 2025, with the total dividend per share standing at ₹123, comprising an interim dividend of ₹75 and a recommended final dividend of ₹48 per equity share.

Strategic Business Transformation

The company continues its strategic transformation focusing on two key pillars: growing the insulin franchise with customer-centric, digitally and AI-empowered capabilities, and implementing a partnership model for the legacy portfolio in cardiovascular, central nervous system, and oral antidiabetic segments. The diabetes portfolio demonstrates strong market positioning with Lantus maintaining a 31% market share and achieving 6% volume acceleration.

Operational Excellence and Cost Management

Sanofi India achieved significant operational efficiency with a 17% reduction in operating expenses for the full year. Total operating expenses decreased to ₹4,489 million from ₹5,431 million in FY24, driven by business optimization and operational expense efficiency measures. Employee costs were reduced by 23% to ₹1,853 million, while other operating expenses declined by 13% to ₹2,636 million.

The financial results were reviewed by the Audit Committee on February 24, 2026, and approved by the Board of Directors on February 25, 2026. The complete financial results are available on BSE, NSE, and the company's official website.

Sanofi India Limited has received a significant tax demand order from the Commercial Tax Officer in Tiruvalur, Tamil Nadu, totaling ₹2.37 crore for the financial year 2021-22. The pharmaceutical company disclosed this development in compliance with SEBI listing regulations on 20th February 2026.

Tax Demand Breakdown

The order issued by the Commercial Tax Officer presents a comprehensive demand structure across multiple components:

Nature of Dispute

The tax controversy stems from Input Tax Credit (ITC) claims related to FY 2020-21 that were subsequently claimed in FY 2021-22. The Commercial Tax Officer dismissed the company's submissions and reconciliations regarding the eligibility of these ITC claims, leading to the substantial tax demand.

Timeline and Receipt Details

The order was originally dated 30th December 2025, but Sanofi India received the communication on 19th February 2026. This timeline indicates a significant delay between the order issuance and the company's receipt of the official communication.

Company's Response Strategy

Sanofi India has indicated its intention to challenge the order through appropriate legal channels. The company stated it would make an appeal before the appellate authorities, suggesting confidence in its position regarding the ITC claims that were disputed by the tax officer.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparency with stakeholders regarding material developments that could impact its operations.